The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
ApexOnco Front Page
Recent articles
What could be the four HengRui assets picked up by Bristol?
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
YL217 will enter phase 1 before Sotio's similarly acting rival, licensed from Biocytogen.
While Sutro shows why it’s shelved luvelta-T.
The company buys Belgium’s EsoBiotec for $425m.
The acquisition of Araris follows a 2023 discovery collaboration.
At long last luvelta-T is shelved, and Sutro seeks a new focus.